Abstract
Beta-blocker therapy remains one of the most fascinating issues in heart failure (HF) clinical practice. These agents, once absolutely contraindicated in patients with HF, have been shown to have the greatest beneficial effects on the patients' prognosis. They have radically changed the clinical course of HF, more than any other agent previously introduced, and are now the cornerstone of current HF treatment.1-3 Beta-blocker therapy contradicted most of the hypotheses on which the treatment of HF was based.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
